AMT’ Glybera Shows Long-term Health Benefits

Amsterdam Molecular Therapeutics’ (AMT) lead product ,Glybera, has demonstrated long-term health benefits in one-time administration.

The data from two clinical trials showed that one administration with Glybera brings significant and clinically important reduction in acute pancreatitis in lipoprotein lipase deficient patients.

The three year follow-up data for the eight patients from the first clinical trial showed a statistically significant, tenfold decrease in the incidence of acute pancreatitis. From the second trial in fourteen patients, one year data are available showing similar results. The data from both trials also confirm that the treatment is well-tolerated and safe.

AMT, a Dutch biopharmaceuticle company, is known for a unique production platform that circumvents the obstacles that have hindered development of gene therapy technologies into drugs. AMT currently has a product pipeline with nine products at different stages of development.